Marta Mejías-Trueba

Hospital Universitario Virgen del Rocío

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Laura Herrera‐Hidalgo

Hospital Universitario Virgen del Rocío

Aitana Rodríguez‐Pérez

Hospital Universitario Virgen del Rocío

María Victoria Gil-Navarro

Hospital Universitario Virgen del Rocío

MV Gil Navarro

Hospital Universitario Virgen del Rocío

Héctor Rodríguez‐Ramallo

Hospital Universitario Virgen del Rocío

Susana Sánchez‐Fidalgo

Universidad de Sevilla

M Alonso Moreno

Bellvitge University Hospital

Ana Belén Guisado-Gil

Hospital Universitario Virgen del Rocío

AB Guisado Gil

Hospital Universitario Virgen del Rocío

Beatriz Fernández-Rubio

Hospital Universitario Virgen del Rocío

Cooperative Institutions

Hospital Universitario Virgen del Rocío

125

Universidad de Sevilla

Instituto de Biomedicina de Sevilla

Instituto de Salud Carlos III

Hospital Universitario Virgen Macarena

Centro de Investigación Biomédica en Red

Andalusian Health Service

Consejo Superior de Investigaciones Científicas

Hospital Juan Ramón Jiménez

Hospital General Universitario Gregorio Marañón

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

NP-007 Validation of antimicrobial defined daily dose for the paediatric population: Final results of KiDDDs project

Elena Montecatine-Alonso Marta Mejías-Trueba MV Gil-Navarro Estibaliz Chavarri-Gil CM Fernández-Llamazares

Background

Antimicrobial stewardship programmes (ASPs) optimise antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by the World Health Organization for the adult population as a consumption indicator.

Objectives

Validate the tool designed in phase I of the KiDDDs project to establish the most appropriate DDD values in the paediatric population.

Material and Methods

This is an observational, retrospective, multicentre study consisting of two phases. The first phase was aimed at the theoretical calculation of paediatric DDD. The second phase constitutes the validation of the study. Antimicrobial prescriptions were collected from the wards of seven Spanish hospitals during 2017 and 2018. Studied variables were age, gender, weight, antimicrobial dose, frequency and route of administration. Those antimicrobials included in the first stage were considered. From the data collected, the total dose of antibiotic received per patient (mg/day) was calculated, subsequently, the median of the resulting DDD per antibiotic (g/day) was obtained (DDD-Phase II) and were compared with the theoretical DDD (DDD-Phase I).

Antimicrobial Stewardship

Defined daily dose

10.1136/ejhpharm-2024-eahp.7

Cite

Citations (0)

Interacción farmacológica entre rifamicinas y anticoagulantes: caso clínico

Farmacia Hospitalaria (2024)

Lupe Rodríguez-de Francisco Rafael Luque‐Márquez Marta Mejías-Trueba Laura Herrera‐Hidalgo María Victoria Gil-Navarro

10.1016/j.farma.2024.03.001

Cite

Citations (0)

Impact of medication reconciliation on health outcomes: An overview of systematic reviews

Research in Social and Administrative Pharmacy (2019)

Ana Belén Guisado-Gil Marta Mejías-Trueba Eva Rocío Alfaro‐Lara Marina Sánchéz‐Hidalgo Nieves Ramírez‐Duque

CINAHL

Grey Literature

10.1016/j.sapharm.2019.10.011

Cite

Citations (22)

Feasibility of the Implementation of LESS-CHRON in Clinical Practice: A Pilot Intervention Study in Older Patients With Multimorbidity

Innovation in Aging (2023)

Marta Mejías-Trueba Aitana Rodríguez‐Pérez Carlos Hernández-Quiles Manuel Ollero‐Baturone Maria Dolores Nieto‐Martín

Abstract Background and Objectives Potentially inappropriate medication refers to the prescription of drugs whose risks outweigh the benefits. There are different pharmacotherapeutic optimization strategies to detect and avoid potentially inappropriate medications (PIMs), namely deprescription. The List of Evidence-Based Deprescribing for Chronic Patients (LESS-CHRON) criteria were designed as a tool to systematize the deprescribing process. LESS-CHRON has established itself as one of the most suitable to be applied in older (≥65 years) multimorbid patients. However, it has not been applied to these patients, to measure the impact on their treatment. For this reason, a pilot study was conducted to analyze the feasibility of implementing this tool in a care pathway. Research Design and Methods A pre–post quasi-experimental study was conducted. Older outpatients with multimorbidity from the Internal Medicine Unit of a benchmark Hospital were included. The main variable was feasibility in clinical practice, understood as the likelihood that the deprescribing intervention recommended by the pharmacist would be applied to the patient. Success rate, therapeutic, and anticholinergic burden, and other variables related to health care utilization were analyzed. Results A total of 95 deprescribing reports were prepared. Forty-three were evaluated by the physician who assessed the recommendations made by pharmacists. This translates into an implementation feasibility of 45.3%. The application of LESS-CHRON identified 92 PIMs. The acceptance rate was 76.7% and after 3 months 82.7% of the stopped drugs remained deprescribed. A reduction in anticholinergic burden and enhanced adherence was achieved. However, no improvement was found in clinical or health care utilization variables. Discussion and Implications The implementation of the tool in a care pathway is feasible. The intervention has achieved great acceptance and deprescribing has been successful in a not insignificant percentage. Future studies with a larger sample size are necessary to obtain more robust results in clinical and health care utilization variables.

Deprescribing

Clinical Practice

10.1093/geroni/igad042

Cite

Citations (2)

Cross-cultural adaptation and validation into Spanish of the deprescription questionnaire in the elderly patient

Medicina Clínica (English Edition) (2022)

Marta Mejías-Trueba Aitana Rodríguez‐Pérez Bosco Barón‐Franco Carlos Hernández-Quiles Bernardo Santos‐Ramos

Cross-Cultural

Cross-validation

Cross-sectional study

10.1016/j.medcle.2022.03.019

Cite

Citations (0)

Prevalence of Potentially Inappropriate Medications in Patients With Multimorbidity According to LESS-CHRON and STOPPFrail Criteria

Journal of the American Medical Directors Association (2023)

Marta Mejías-Trueba Aitana Rodríguez‐Pérez Irene Sotillo-Sánchez Susana Sánchez‐Fidalgo Maria Dolores Nieto‐Martín

Interquartile range

Deprescribing

Cross-sectional study

10.1016/j.jamda.2022.12.013

Cite

Citations (3)

Adaptación transcultural y validación al español del cuestionario de desprescripción en el paciente de edad avanzada

Medicina Clínica (2022)

Marta Mejías-Trueba Aitana Rodríguez‐Pérez Bosco Barón‐Franco Carlos Hernández-Quiles Bernardo Santos‐Ramos

10.1016/j.medcli.2022.03.022

Cite

Citations (1)

Las estatinas en el tratamiento de la enfermedad del alzheimer

Marta Mejías-Trueba

Source

Cite

Citations (0)

4CPS-250 Experience of tecovirimat and cidofovir use in a patient with monkeypox: a case report

Lupe Rodríguez-de Francisco AB Guisado-Gil Marta Mejías-Trueba Laura Herrera‐Hidalgo Santiago José Lora-Escobar

Background and Importance

Current treatment for Monkeypox's disease (MPXV) is mainly symptomatic. However, in immunocompromised patients, hospitalisation and treatment with antiviral drugs may be necessary. With the recent outbreak of MPXV, new strategies have been proposed.

Aim and Objectives

The aim of the study was to describe our clinical experience with tecovirimat and cidofovir in the treatment of MPXV in a patient whose CD4+ lymphocyte level is less than 50 cells/ml.

Material and Methods

The effectiveness of tecovirimat-cidofovir was assessed by the evolution of the rash from macule to crusts that dry up and fall off.

Results

The patient was a 35-year-old man diagnosed with MPXV who presented skin lesions in the perineal area, extremities, face, trunk and back and severe proctitis. At admission, the patient was diagnosed with HIV (severely immunosuppressed with CD4+ lymphocyte levels of <40 cells/ml), so he was started on antiretroviral treatment (BIC/TAF/TDF). Sexually transmitted infection screening detected Chlamydia trachomatis infection, which was treated with doxycycline. In the context of MPXV proctitis, it was decided to apply for tecovirimat, the antiviral treatment of choice. The dosage for tecovirimat is weight-based, 600 mg was administered every 12 hours for 14 days (30/08/22–12/09/22). Regarding effectiveness, no new lesions were observed and those already present were regressing, except in the perianal area, where the lesions continued to progress. Therefore, it was decided to administer intravenous cidofovir 5 mg/kg twice weekly (09/09/22, 16/09/22). To avoid toxicity, oral probenecid was administered concomitantly: 2 g 3 hours before and 1 g 2 and 8 hours after completing the perfusion, in addition to 0.9% saline solution 1000 ml 1 h before. After the treatment, there was a progression of lesions in the right inguinal region, palpating left inguinal adenopathy and intense involvement of the testicle, groin and perineal area.

Conclusion and Relevance

In contrast to previous cases of patients whose CD4+ lymphocyte levels were above 500 cells/ml, the treatment with tecovirimat and cidofovir in this patient did not achieve a satisfactory response due to the continuous appearance of new lesions. The severe immunosuppression could probably explain the aggressive development of the disease.

References and/or Acknowledgements

Conflict of Interest

No conflict of interest

Cidofovir

10.1136/ejhpharm-2023-eahp.431

Cite

Citations (0)

Traducción y adaptación transcultural al español de la escala MULTIPleS en pacientes de edad avanzada con multimorbilidad

Medicina Clínica (2022)

Marta Mejías-Trueba Beatriz Fernández-Rubio Clara López-Hermoso Gemma Fernández-Rubio Carlos Jiménez-De Juan

Multiple

10.1016/j.medcli.2022.01.026

Cite

Citations (1)